An Open Label, Multicenter Phase 1-2 Study to Investigate the Effectiveness, Safety and Immunogenicity of a Monotherapy With Intradermal IMA910 Plus GM-CSF Following Pre-treatment With Low-dose Cyclophosphamide in Advanced Colorectal Carcinoma Patients Who Have Successfully Completed a 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy.
This is a multicentre, open-label, Phase 1-2 study in patients with locally advanced and/or
metastatic colorectal cancer (CRC) to investigate the effectiveness, safety and
immunogenicity of the tumour multi-peptide vaccine IMA910 plus GM-CSF (1st cohort) given as
monotherapy after successful (CR, PR or SD) completion of a 12 week first-line
oxaliplatin-based standard chemotherapy (e.g. FOLFOX, XELOX). Safety, immunogenicity and
effectiveness of IMA910 plus GM-CSF in combination with imiquimod will be investigated in a
2nd cohort of patients with locally advanced and/or metastatic colorectal cancer (CRC) after
successful (CR, PR or SD) completion of a 12 week first-line oxaliplatin-based standard
chemotherapy (e.g. FOLFOX, XELOX).
The aim of this study is to investigate whether IMA910 plus GM-CSF (1st cohort) is an
effective maintenance therapy with a favorable toxicity profile. A single dose of low-dose
cyclophosphamide is applied as an immune modulator 3 days before the start of vaccination.
Effectiveness is measured in terms of the disease control rate (DCR) at Visit 14 (= 27 weeks
of vaccination) according to RECIST. The baseline tumour response assessment is performed
after a first-line oxaliplatin-based standard chemotherapy for 12 weeks. The DCR is compared
to a no effect level of 21% derived from the PFS curve of the chemotherapy-free interval
cohort (arm B) of the OPTIMOX 2 study. Tumour response assessments will be performed every 9
weeks according to RECIST. Further a 2nd cohort of patients will be treated with IMA910 plus
GM-CSF in combination with imiquimod and a single dose of lowdose cyclophosphamide. The aim
of the 2nd cohort is to investigate whether the addition of imiquimod is safe, enhances the
immune response to IMA910 and shows effectiveness.
Patients in the 1st and 2nd cohort will be withdrawn from study treatment once a progress
according to RECIST is noted. An enrolment plan for the first 6 patients included into the
1st cohort will be part of this study to ensure maximum safety of the study participants.
The enrollment of the first 6 patients into the 2nd cohort will also follow an enrolment
plan to ensure maximum safety.
Patients must be HLA-A*02-positive. Patients must have been diagnosed with unresectable,
locally advanced and/or metastatic colorectal cancer before first-line chemotherapy.
Patients must have completed a 12 week first-line oxaliplatin-based standard chemotherapy
(e.g. FOLFOX or XELOX) with either complete or partial response or stable disease as the
outcome. In case the 12 week first-line oxaliplatin-based standard chemotherapy results in
resectable disease the patient may not be enrolled and routinely undergoes surgical
resection of residual tumour. Patients must be aged 18 years or older and must have
histological confirmed colorectal adenocarcinoma (CRC) and radiological evidence (CT/MRI) of
unresectable locally advanced and/or metastatic CRC prior to 12 week first-line
oxaliplatin-based standard chemotherapy.
This study will employ low-dose Cyclophosphamide (administered as a single i.v. infusion at
a dose of 300 mg/m2 3 days prior to the vaccination) in order to increase the immune
response to IMA910 (5.78 mg i.d.). Patients will receive 7 vaccinations of IMA910 plus
GM-CSF (75 μg i.d.) in the first 6 weeks of treatment (induction period) followed by 9
vaccinations at 3-week intervals for a further 27 weeks (maintenance period). The patients
will receive a total of 16 vaccinations over a period of 33 weeks. An end of study visit
(EOS, Visit 17) will be performed 4 weeks after the last treatment. Patients enrolled into
the 2nd cohort of the study will receive the same treatment as described above and will
additionally receive a topical application of 250 mg imiquimod cream (12.5 mg imiquimod) 10
minutes (up to 20 minutes) after each application of IMA910 (Visit 1-16) and from day 3
onwards 250 mg imiquimod cream (12.5 mg imiquimod) 24 hours (but up to 48 hours at the
latest) after each application of IMA910 (Visit 3-16). The topical application of imiquimod
additionally 24 hours (but up to 48 hours at the latest) after IMA910 application will be
done by the patient at home. Imiquimod cream will be applied to a marked 5x5 cm area around
the injection site of GM-CSF and IMA910.
At screening a CT or MRI of the chest and abdomen/pelvis will be performed to assess
baseline tumour status. In patients with suspected brain metastasis at Screening or if
clinically indicated a CT or MRI of the brain will be performed. In patients with known bone
metastases of the extremities or in case of suspected bone metastases of the extremities at
Screening correlative imaging (X-ray, CT or MRI) has to be performed of the respective
area(s). At Visits 8, 11, 14, and 17 (EOS) a CT or MRI of the chest, abdomen and pelvis will
be performed. In patients with bone metastases of the extremities detected at baseline or
during the study, repeat assessments of the sites of bone metastases (X-ray, CT or MRI) will
be performed at Visits 14 and 17 (EOS). An assessment of brain metastasis will be performed
only if clinically indicated during the course of the study.
Cellular immunomonitoring (T-cell responses to peptides contained in IMA910 and analysis of
other immune cell populations that may influence T-cell responses such as Tregs), serum
levels of antibodies and molecules with suspected influence on immune response will be
assessed on several occasions during the study. In a subgroup of patients the following
parameters may be assessed in tumour tissue (depending on the amount and quality of tissue):
expression of target genes encoding the TUMAPs contained in IMA910 and of genes which might
be influenced by IMA910, presentation of TUMAPs contained in IMA910, presence of tumour
infiltrating lymphocytes and presence of molecules with suspected influence on immune
Safety assessment will comprise continuous adverse event reporting, regular physical
examinations and regular assessments of vital signs, haematology, blood chemistry and urine.
A 12-lead ECG will be performed at screening and at the end of the study. Pregnancy testing
will be performed according to applicable legislation in the country where the trial is
being performed. At the very least, women of childbearing potential must undergo a pregnancy
test during screening for the study, before the first dose and at the end of the study.
In the initial phase of the study 6 patients of the 1st Cohort will be treated step-wise and
observed for 21 days according to a pre-specified enrolment plan. The first step is the
enrolment of 1 patient followed by an observation period of 21 days, thereafter enrolment of
2 patients followed by an observation period of 21 days thereafter 3 patients followed by an
observation period of 21 days. The sponsor will evaluate the adverse events and laboratory
data following every enrolment step and initiate the enrolment of the next enrolment step.
After 6 patients enrolled in that way the subsequent enrolment can be performed without
Further also in the 2nd Cohort the first 6 patients of the 2nd cohort will be enrolled in a
step-wise manner. The first step is the enrolment of 1 patient followed by an observation
period of 1 week, thereafter enrolment of 2 patients followed by an observation period of 1
week thereafter enrolment of 3 patients followed by an observation period of 1 week. The
sponsor will evaluate the adverse events following every enrolment step and initiate the
enrolment of the next enrolment step. After 6 patients enrolled in that way the subsequent
enrolment can be performed without further restrictions.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Disease control rate
after 27 weeks of vaccination
immatics biotechnolgies GmbH
Belgium: Federal Agency for Medicinal Products and Health Products
EudraCT Nr. 2007-005666-12